HC Wainwright initiated coverage on shares of Audentes Therapeutics (NASDAQ:BOLD) in a report issued on Wednesday morning. The firm issued a buy rating and a $37.00 target price on the biotechnology company’s stock.

Other analysts have also issued research reports about the stock. BidaskClub upgraded shares of Audentes Therapeutics from a buy rating to a strong-buy rating in a research note on Wednesday. Bank of America reiterated a buy rating and issued a $33.00 price objective (up previously from $23.00) on shares of Audentes Therapeutics in a research note on Friday, September 22nd. Raymond James Financial assumed coverage on shares of Audentes Therapeutics in a research note on Thursday, October 12th. They issued a market perform rating for the company. William Blair assumed coverage on shares of Audentes Therapeutics in a research note on Tuesday, October 17th. They issued an outperform rating and a $35.00 price objective for the company. Finally, ValuEngine lowered shares of Audentes Therapeutics from a hold rating to a sell rating in a research note on Friday, December 1st. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. The company has an average rating of Buy and an average target price of $29.38.

Audentes Therapeutics (BOLD) traded down $0.40 during trading on Wednesday, reaching $31.02. 203,100 shares of the company’s stock traded hands, compared to its average volume of 152,465. Audentes Therapeutics has a 52-week low of $13.90 and a 52-week high of $33.43.

Audentes Therapeutics (NASDAQ:BOLD) last released its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.88) earnings per share for the quarter, meeting the consensus estimate of ($0.88). sell-side analysts forecast that Audentes Therapeutics will post -3.52 earnings per share for the current year.

In other Audentes Therapeutics news, VP Suyash Prasad sold 8,000 shares of the business’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $28.53, for a total transaction of $228,240.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP David Nagler sold 3,750 shares of the business’s stock in a transaction on Wednesday, September 27th. The shares were sold at an average price of $30.00, for a total transaction of $112,500.00. Following the sale, the senior vice president now owns 3,750 shares of the company’s stock, valued at approximately $112,500. The disclosure for this sale can be found here. Insiders have sold a total of 747,750 shares of company stock valued at $21,112,750 in the last 90 days. 47.30% of the stock is currently owned by company insiders.

A number of hedge funds have recently made changes to their positions in BOLD. Bank of America Corp DE increased its stake in Audentes Therapeutics by 22.6% during the 1st quarter. Bank of America Corp DE now owns 23,399 shares of the biotechnology company’s stock valued at $399,000 after purchasing an additional 4,310 shares in the last quarter. TD Asset Management Inc. increased its stake in Audentes Therapeutics by 2.4% during the 2nd quarter. TD Asset Management Inc. now owns 25,280 shares of the biotechnology company’s stock valued at $484,000 after purchasing an additional 598 shares in the last quarter. Schwab Charles Investment Management Inc. increased its stake in Audentes Therapeutics by 139.3% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 25,600 shares of the biotechnology company’s stock valued at $490,000 after purchasing an additional 14,900 shares in the last quarter. Rhumbline Advisers bought a new stake in Audentes Therapeutics during the 2nd quarter valued at $252,000. Finally, State of Wisconsin Investment Board bought a new stake in Audentes Therapeutics during the 2nd quarter valued at $210,000. Institutional investors and hedge funds own 78.95% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Audentes Therapeutics (BOLD) Coverage Initiated by Analysts at HC Wainwright” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://www.watchlistnews.com/audentes-therapeutics-bold-coverage-initiated-by-analysts-at-hc-wainwright/1776349.html.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.